1,726,754 research outputs found
Mandurama photograph collection [2755] [picture] /
No full textAlso available in an electronic version via the Internet at: http://nla.gov.au/nla.pic-an8526486-2755
Astronomische Nachrichten, nos 2755-2760
No full textRadau Rodolphe. Astronomische Nachrichten, nos 2755-2760. In: Bulletin astronomique, tome 3, 1886. pp. 609-616
Safety, tolerability and pharmakocinetic properties of the novel Triazene TriN 2755 in tumor bearing dogs
Get PDFTriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use which carries the triazene group as cytotoxic principle. The purpose of the study was to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic (PK) profile of TriN 2755 in tumor bearing dogs. Additionally, tumor response was monitored and assessed after chemotherapy as a secondary goal. Treatment schedule consisted of IV administration of the drug over 20 minutes on two consecutive weeks per month for a total of three cycles. Thirty tumor bearing dogs were included in the study. The starting dose was 25 mg/kg and the escalation steps occurred in increments of 20% of the previous dose. The MTD was 74.6 mg/kg. The DLT was characterized by gastrointestinal adverse events only. The pharmacokinetic of TriN 2755 and its main metabolites in plasma and sputum are described in a two compartment model. The response rate for 19/30 dogs was 47.3% (6 partial remission, 3 stable disease) and the median progression-free interval (PFI) for the responders was 47d (range 21-450d). In summary, this study demonstrated a safe and tolerable dose of TriN 2755 for IV use in tumor bearing dogs. The adverse events were mild in severity and limited only in fatigue and gastrointestinal upset. = TriN 2755 ist eine alkylierende, antineoplastische Substanz für intravenöse (IV) Verabreichung, das die Triazenegrouppe als zytotoxisches Prinzip trägt. Ziel dieser Studie war die Bestimmung der maximalen tolerierbaren Dosis (MTD), der Dosis-limitierenden Toxizität (DLT) und des pharmakokinetischen Profils von TriN 2755 in Hunden mit Tumoren. Die Ansprache auf die Chemotherapie wurde zusätzlich als sekundäres Ziel kontrolliert und bewertet. Der Behandlungsplan bestand aus der IV Verabreichung von TriN 2755 über 20 Minuten an zwei aufeinanderfolgenden Wochen pro Monat für drei Zyklen. Dreissig Hunden mit Tumoren wurden in die Studie eingeschlossen. Die Anfangsdosis war 25 mg/kg und die Eskalationsstufen erfolgten in 20%-Schritten der vorherigen Dosis. Die MTD war 74,6 mg/kg. Als dosis-limitierende Toxizität wurden nur gastrointestinale Nebenwirkungen beobachtet. Die Pharmakokinetik von TriN 2755 und seinen Hauptmetaboliten im Plasma und Sputum sind in einem zwei Kompartiment-Modell beschrieben. Die Ansprache-Rate für 19/30 Hunde erreichte 47,3% (6 partielle Remission und 3 stabile Erkrankung) und die mediane progressionsfreie Intervall für die Hunde, die angesprochen haben, war 47 Tage (21-450 Tage). Zusammenfassend konnte in dieser Studie gezeigt werden, dass es nebenwirkungsarme, tolerierbare Dosis von TriN 2755 für IV Verabreichung bei Hunden mit Tumoren gibt. Die Nebenwirkungen waren mild und selbstlimitierend, aus Müdigkeit und gastrointestinale Störungen bestehend
Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumor bearing dogs
Get PDFTriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use, carrying the triazene group as the cytotoxic principal. Using a standard 3 + 3 design, a phase I study was performed in tumour bearing dogs to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic (PK) profile of TriN 2755. Thirty dogs were included in the study. TriN 2755 was administered over 20 min on two consecutive weeks per month for a total of three cycles. The starting dose was 25 mg kg-1 and the MTD was 74.6 mg kg-1 . Three dogs experienced DLT, which was characterized by gastrointestinal adverse events. The PKs of TriN 2755 and its main metabolites in plasma and sputum are described in a two-compartment model. The response rate for 19 of 30 dogs was 47.3% (six partial remission, three stable disease) and the median progression-free interval (PFI) for the responders was 47 days (range: 21-450 days)
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
2755. Rodericus, archiepiscopus Toletanus, De rebus Hispaniae libri IX
No full text2755. Rodericus, archiepiscopus Toletanus, De rebus Hispaniae libri IX. In: Molinier Auguste. Les Sources de l'histoire de France - Des origines aux guerres d'Italie (1494). III. Les Capétiens, 1180-1328. Paris : A. Picard et fils, 1903. pp. 162-163
Steele, John, b. 1772 (SC 2755)
Get PDFFinding aid and full text transcription (Click on Additional Files ) of Manuscripts Small Collection 2755. Letter of John Steele, 16 February 1802, written from Bourbon County, Kentucky, to Reverend John Hemphill, Chester County, South Carolina. He describes the behavior of worshippers at the religious revivals in his part of the country, and expresses concern about their departure from orthodox principles of religion
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
- …
